Analyst Ratings January 26, 2026

UBS Lowers Clearwater Analytics Rating to Neutral After Buyout Agreement

Bank trims price target to $24.55 as acquisition led by Permira and Warburg Pincus advances toward closing

By Sofia Navarro CWAN
UBS Lowers Clearwater Analytics Rating to Neutral After Buyout Agreement
CWAN

UBS has downgraded Clearwater Analytics Holdings (CWAN) from Buy to Neutral and cut its price target to $24.55 following the company's agreement to be acquired by an investor group led by Permira and Warburg Pincus. The cash deal values Clearwater at $24.55 per share, equating to roughly 7.7 times UBS's sales estimate, and the transaction is expected to close in the first half of 2026 subject to approvals.

Key Points

  • UBS downgraded Clearwater Analytics (CWAN) from Buy to Neutral and lowered its price target to $24.55 from $30.00 following the company's acquisition agreement.
  • The acquisition values Clearwater at $24.55 per share in cash - roughly 7.7 times UBS's estimated sales - and the transaction is expected to close in the first half of 2026 pending approvals.
  • Other notable market positions include RBC Capital's Outperform with a $36.00 target and DA Davidson shifting to Neutral with a $24.55 target; activist Starboard Value LP holds nearly a 5% stake and has pressed for a full sales process.

UBS has revised its recommendation on Clearwater Analytics Holdings (CWAN) to Neutral from Buy and lowered its price target to $24.55 from $30.00 after the software company agreed to be acquired by an investor consortium. The bank's move follows the announced cash agreement that prices the company at $24.55 per share.

At the time of UBS's action, Clearwater shares were trading near $24.18. Independent data shows the company's Fair Value estimate is closely aligned with both the market price and the per-share acquisition offer.


Deal specifics and financial posture

Clearwater disclosed on December 21 that an investor group led by Permira and Warburg Pincus - the buyout firms involved when the company listed in 2021 - had reached an agreement to buy Clearwater. Under the terms, the acquisition carries a cash price of $24.55 per share, a valuation UBS notes is about 7.7 times its estimate of the company's sales.

Company-level financial metrics referenced in available data indicate Clearwater retains a solid liquidity profile, with a Current Ratio reported at 1.97, meaning current assets comfortably cover short-term obligations.


Timing, approvals and market mechanics

UBS highlighted that the transaction's go-shop period ended on January 23 with no alternative proposals emerging. While shareholder and regulatory sign-offs are still required, the bank's base case assumes the transaction will proceed to close. Management and the investor group anticipate completing the deal in the first half of 2026, at which point Clearwater would be taken private.

UBS cautioned that, until the deal is consummated, CWAN shares are likely to trade on the basis of deal-related developments rather than the firm's operating fundamentals.


Other analyst positions and shareholder actions

Not all sell-side opinions moved in step with UBS. RBC Capital retained an Outperform rating and kept a $36.00 price target on Clearwater. DA Davidson adjusted its stance to Neutral from Buy and set a $24.55 price target in light of the pending transaction. Earlier commentary from DA Davidson had reiterated a Buy rating with a $30.00 target after activist investor Starboard Value LP took nearly a 5% stake in the company.

Starboard has been reported as urging Clearwater to pursue a full sales process conducted with independent advisers.


Product development and investor signals

Amid the acquisition process, Clearwater launched the CWAN Duration Activity Index (CDAI), an index designed to reflect institutional duration positioning. The index's initial readings indicate institutional investors are holding neutral duration exposure as interest rates find footing.


What to watch next

The principal near-term items to monitor are progress toward shareholder and regulatory approvals and any market activity that might arise during the period before closing. With the go-shop period concluded and no alternative bids announced, the transaction's timeline toward privatization in the first half of 2026 remains the focal point for investors and analysts following the stock.

Risks

  • Shareholder and regulatory approvals are still required for the transaction to close - delays or denials could affect timing and valuation (impacts: equity markets and corporate M&A activity).
  • Until the deal is completed, CWAN's share price may be influenced more by deal dynamics than by operating fundamentals, increasing short-term volatility (impacts: investors and market liquidity).
  • The absence of alternative proposals after the go-shop period could limit competitive negotiation leverage and leave the current offer as the prevailing price point (impacts: M&A pricing and private equity negotiations).

More from Analyst Ratings

Evercore ISI Sticks with Outperform on Apple, Sets $330 Target Backed by App Store and Services Strength Feb 2, 2026 Deutsche Bank Says AppLovin Risk-Reward Looks Better After Google’s Project Genie Shock Feb 2, 2026 Raymond James Sticks With Market Perform on American Airlines Despite Stronger Guidance and Faster Debt Paydown Feb 2, 2026 Mizuho Sticks with Outperform on Robinhood as UK ISA Launch Seen as Growth Lever Feb 2, 2026 Freedom Capital Lifts Caterpillar Price Target to $700 but Keeps Hold Rating Feb 2, 2026